Sara Nunnery, MD, director of breast cancer research at Tennessee Oncology, outlines key considerations when deciding whether to offer trastuzumab deruxtecan to patients with HER2-low or HER2-ultralow metastatic breast cancer. Dr. Nunnery explains how clinical factors, treatment setting (IV vs oral), and patient preferences around quality of life all play a role in determining the ideal candidate for this therapy.
HER2-Low Metastatic
Advertisement
Zanidatamab plus chemo showed promising responses in HER2+ and HER2-low mBC, with durable activity in a phase I trial.
Higher fat mass and lower fat density linked to increased T-DXd dose reductions and toxicity in metastatic breast cancer.
Dr. Nunnery discusses HER2-low and ultralow testing and Enhertu’s role after DESTINY-Breast06 in metastatic breast cancer.
Enhertu approved in the EU for HR+, HER2-low, -ultralow metastatic breast cancer, showing PFS benefit over chemotherapy.
Cytology provides new insights into HER2-low metastatic breast cancer, revealing proliferative features and survival trends.
A new study validates a HER2-low–focused scoring system to improve diagnostic accuracy in metastatic breast cancer.
Study finds HER2-low vs HER2-zero breast cancer similar overall, but HER2-low shows better RFS if node-positive.
The FDA approved trastuzumab deruxtecan for HR-positive/HER2-low metastatic breast cancer based on DESTINY-Breast06 results.
The FDA granted Fast Track status to emiltatug ledadotin for advanced breast cancer following phase 1 results targeting B7-H4
Dr. Lopetegui-Lia reacts to Dr. Gatti-Mays' breast cancer panel discussion from Advancements in Oncology.
Dr. Margaret Gatti-Mays delves into the topic of HER2 tumor expression in breast cancer.
Dr. Margaret Gatti-Mays talks with The Oncology Brothers about the right treatments for endocrine-resistant breast cancer.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.